The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. (2021)
Attributed to:
United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(21)00004-7
PubMed Identifier: 33971168
Publication URI: http://europepmc.org/abstract/MED/33971168
Type: Journal Article/Review
Volume: 9
Parent Publication: The Lancet. Respiratory medicine
Issue: 10
ISSN: 2213-2600